PRESS RELEASE DUBLIN.

For the 12 months endingJune 30, 2015, Noxafil® had global sales of approximately$143.6 million, regarding toIMS Healthdata.. PRESS RELEASE DUBLIN,Aug. 11, 2015/PRNewswire/ –Allergan plc today confirmed that it has filed an Abbreviated New Medication Application with theU.S. Food and Drug Administration seeking approval to advertise Posaconazole Delayed-Release Tablets, 100mg.Allergan'sANDA product is a generic version of Merck's Noxafil®which is an antifungal agent indicated for prophylaxis of invasiveAspergillusandCandidainfections in patients, 13 years of age and older, who are in high-risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplantation recipients with graft-versus-web host disease or people that have hematologic malignancies with prolonged neutropenia from chemotherapy.The missing-indicator method was used to take into account missing information.26 Cumulative incidence curves were estimated by way of the method of Good and Gray27 and were weighed against the use of log-rank tests. Cox regression versions with the time after a cancers diagnosis as enough time level were used to determine hazard ratios with 95 percent self-confidence intervals. Multivariable Cox models were adjusted for age group at diagnosis; cancers stage ; status with regard to chemotherapy, radiotherapy, analysis of coronary disease before tumor, and analysis of diabetes mellitus before cancer; 12 months of birth; sex; race and ethnic descent ; highest level of education; and size of residential area.